Antibody-Drug Conjugate Therapy

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 821-855

  Alley, Stephen C ^a   Benjamin, Dennis ^a   Law, Che Leung ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

Antibody drug conjugate therapy; Linker choice drug linker stability; Tumor cell surface targets for ADCs

Indexed keywords

EID: 80053490236     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch35     Document Type: Chapter

References (222)

1. Aboukameel, A., A.-S. Goustin, R. Mohammad, et al. 2007. Superior anti-tumor activity of the CD19-directed immunotoxin, SAR3419 to rituximab in non-Hodgkins xenograft animal models: Preclinical evaluation. AbstractNo. 2339. Blood 110(11).
2. Adams, G.P., R. Schier, A.M. McCall, et al. 2001. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61:4750-4755.
3. Agathanggelou, A., G. Niedobitek, R. Chen, et al. 1995. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am. J. Pathol. 147:1152-1160.
4. Akiyama, H., K.A. Mohamedali, R.L. E Silva, et al. 2005. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein. Mol. Pharmacol. 68:1543-1550.
5. Al-Ejeh, F., J.M. Darby, and M.P. Brown. 2007. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs. Clin. CancerRes. 13:5509s-5518s.
6. Al-Ejeh, F., J.M. Darby, K. Pensa, et al. 2007. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen. Clin. Cancer Res. 13:5519s-5527s.
7. Alley, S.C., D.R. Benjamin, S.C. Jeffrey, et al. 2008. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19:759-765.
8. Altschuler, Y., C.L. Kinlough, P.A. Poland, et al. 2000. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol. Biol. Cell 11:819-831.
9. Arcamone, F., G. Cassinelli, G. Fantini, et al. 1969. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol. Bioeng. 11:1101-1110.
10. Austin, C.D., X. Wen, L. Gazzard, et al. 2005. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc. Natl. Acad. Sci. U.S.A. 102:17987-17992.
11. Bai, R.L., G.R. Pettit, and E. Hamel. 1990. Binding ofdolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 265:17141-17149.
12. Beeram, M., I. Krop, S. Modi, et al. 2007. A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC). AbstractNo. 1042. J. Clin. Oncol. 25(18S).
13. Bhaskar, V., D.A. Law, E. Ibsen, et al. 2003. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 63:6387-6394.
14. Boghaert, E.R., K.M. Khandke, L. Sridharan, et al. 2008. Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 mul) blood samples. Cancer Chemother. Pharmacol. 61:1027-1035.
15. Boghaert, E.R., L. Sridharan, D.C. Armellino, et al. 2004. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin. Cancer Res. 10:4538-4549.
16. Bonifacino, J.S., and L.M. Traub. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72:395-447.
17. Breton, J., N. Pezzi, A. Molinari, et al. 1995. Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. Eur. J. Biochem. 231:563-569.
18. Bross, P.F., J. Beitz, G. Chen, et al. 2001. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7:1490-1496.
19. Bumol, T.F., A.L. Baker, E.L. Andrews, et al. 1988. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies. Targeted Diagn. Ther. 1:55-79.
20. Carter, P., L. Smith, and M. Ryan. 2004. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr. Relat. Cancer 11:659-687.
21. Cassady, J.M., K.K. Chan, H.G. Floss, et al. 2004. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull. (Tokyo) 52:1-26.
22. Cassard, S., J. Salamero, D. Hanau, et al. 1998. A tyrosine-based signal present in Ig alpha mediates B cell receptor constitutive internalization. J. Immunol. 160:1767-1773.
23. Chahlavi, A., P. Rayman, A.L. Richmond, et al. 2005. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70. Cancer Res. 65:5428-5438.
24. Chan, S.Y., A.N. Gordon, R.E. Coleman, et al. 2003. A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol. Immunother. 52:243-248.
25. Chari, R.V., B.A. Martell, J.L. Gross, et al. 1992. Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res. 52:127-131.
26. Chen, Q., H.J. Millar, F.L. McCabe, et al. 2007a. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models. Clin. Cancer Res. 13:3689-3695.
27. Chen, Y., S. Clark, T. Wong, et al. 2007b. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 67:4924-4932.
28. Crocker, P.R., J.C. Paulson, and A. Varki. 2007. Siglecs and their roles in the immune system. Nature Rev. Immunol. 7:255-266.
29. d'Azzo, A., A. Bongiovanni, and T. Nastasi. 2005. E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic 6:429-441.
30. Deryugina, E.I., and J.P. Quigley. 2006. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 25:9-34.
31. DiJoseph, J.F., M.M. Dougher, D.C. Armellino, et al. 2007a. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21:2240-2245.
32. DiJoseph, J.F., M.M. Dougher, D.C. Armellino, et al. 2007b. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol. Immunother. 56:1107-1117.
33. Doronina, S.O., B.A. Mendelsohn, T.D. Bovee, et al. 2006. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17:114-124.
34. Doronina, S.O., B.E. Toki, M.Y. Torgov, et al. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol. 21:778-784.
35. Dowell, J.A., J. Korth-Bradley, H. Liu, et al. 2001. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41:1206-1214.
36. Dubowchik, G.M., and R.A. Firestone. 1998. Cathepsin B-sensitive dipeptide prodrugs. I. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 8:3341-3346.
37. Dubowchik, G.M., K. Mosure, J.O. Knipe, et al. 1998. Cathepsin B-sensitive dipeptide prodrugs. II. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett. 8:3347-3352.
38. Duffy, M.J. 2004. The urokinase plasminogen activator system: Role in malignancy. Curr. Pharm. Design 10:39-49.
39. Dunphy, C.H., L.J. Gardner, and C.S. Bee. 2000. Malignant mesothelioma with CD30-positivity. A case report and review of the literature. Arch. Pathol. Lab. Med. 124:1077-1079.
40. Durkop, H., H.D. Foss, F. Eitelbach, et al. 2000. Expression of the CD30 antigen in non-lymphoid tissues and cells. J. Pathol. 190:613-618.
41. Eigenbrot, C.W., inventor; Genentech, assignee. 2007. Cysteine engineered antibodies and conjugates. U.S. Patent 20070092940.
42. Erickson, H.K., P.U. Park, W.C. Widdison, et al. 2006. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66:4426-4433.
43. Filpula, D. 2007. Antibody engineering and modification technologies. Biomol. Eng. 24:201-215.
44. Francisco, J.A., C.G. Cerveny, D.L. Meyer, et al. 2003. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465.
45. Garnett, M.C. 2001. Targeted drug conjugates: Principles and progress. Adv. Drug Deliv. Rev. 53:171-216.
46. Gerber, H.P., I.S. Grewal, and E. Oflazoglu. 2009. The role of vascular targeting agents in the treatment of solid tumors: Current and future developments. In Emerging Protein Biotherapeutics, ed. I.S. Grewal.
47. Ghetie, V., S. Popov, J. Borvak, et al. 1997. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnol. 15:637-640.
48. Ghetie, V., and E.S. Ward. 1997. FcRn: The MHC class I-related receptor that is more than an IgG transporter. Immunol. Today 18:592-598.
49. Ghetie, V., and E.S. Ward. 2002. Transcytosis and catabolism of antibody. Immunol. Res. 25:97-113.
50. Gilboa, L., R. Ben-Levy, Y. Yarden, et al. 1995. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits. J. Biol. Chem. 270:7061-7067.
51. Giles, F., R. Morariu-Zamfir, J. Lambert, et al. 2006. Phase I study of AVE9633, an anti-CD33-maytansinoid immunoconjugate, administered as an intravenous infusion in patients with refractory/relapsed CD33-positive acute myeloid leukemia (AML). Abstract No. 4548. Blood 108.
52. Gillespie, A.M., T.J. Broadhead, S.Y. Chan, et al. 2000. Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol. 11:735-741.
53. Golay, J., N. Di Gaetano, D. Amico, et al. 2005. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128:310-317.
54. Grassart, A., A. Dujeancourt, P.B. Lazarow, et al. 2008. Clathrin-independent endocytosis used by the IL-2 receptor is regulated by Rac1, Pak1 and Pak2. EMBO Rep. 9:356-362.
55. Griffiths, G.L., M.J. Mattes, R. Stein, et al. 2003. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin. Cancer Res. 9:6567-6571.
56. Guillemard, V., and H. Uri Saragovi. 2004. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23:3613-3621.
57. Hamann, P.R., L.M. Hinman, C.F. Beyer, et al. 2005a. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug. Chem. 16:346-353.
58. Hamann, P.R., L.M. Hinman, C.F. Beyer, et al. 2005b. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug. Chem. 16:354-360.
59. Hamann, P.R., L.M. Hinman, I. Hollander, et al. 2002. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13:47-58.
60. Hamblett, K.J., P.D. Senter, D.F. Chace, et al. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10:7063-7070.
61. Harmsen, M.M., and H.J. De Haard. 2007. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 77:13-22.
62. Helft, P.R., R.L. Schilsky, F.J. Hoke, et al. 2004. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin. Cancer Res. 10:4363-4368.
63. Henry, M.D., S. Wen, M.D. Silva, et al. 2004. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64:7995-8001.
64. Hey, T., E. Fiedler, R. Rudolph, et al. 2005. Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 23:514-522.
65. Hicke, L., and R. Dunn. 2003. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19:141-172.
66. Higashide, E., M. Asai, K. Ootsu, et al. 1977. Ansamitocin, a group of novel maytansinoid antibiotics with antitu-mour properties from Nocardia. Nature 270:721-722.
67. Hishima, T., M. Fukayama, Y. Hayashi, et al. 2000. CD70 expression in thymic carcinoma. Am. J. Surg. Pathol. 24:742-746.
68. Ho, S.B., G.A. Niehans, C. Lyftogt, et al. 1993. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53:641-651.
69. Hofmann, M.W., S. Honing, D. Rodionov, et al. 1999. The leucine-based sorting motifs in the cytoplasmic domain of the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their medium chains. J. Biol. Chem. 274:36153-36158.
70. Ingle, G.S., P. Chan, J.M. Elliott, et al. 2008. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate. Br. J. Haematol. 140:46-58.
71. Ishitsuka, K., S. Jimi, V.S. Goldmacher, et al. 2008. Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): A potential therapeutic modality implication against natural killer/T cell malignancy. Br. J. Haematol. 141:129-131.
72. Iwahashi, T., Y. Tone, J. Usui, et al. 1989. Selective killing of carcinoembryonic-antigen (CEA)-producing cells in vitro by the immunoconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208. Cancer Immunol. Immunother. 30:239-246.
73. Jain, M., N. Kamal, and S.K. Batra. 2007. Engineering antibodies for clinical applications. Trends Biotechnol. 25:307-316.
74. Jedema, I., R.M. Barge, V.H. van der Velden, et al. 2004. Internalization and cell cycle-dependent killing of leu-kemic cells by gemtuzumab ozogamicin: Rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 18:316-325.
75. Jeffrey, S.C., J.B. Andreyka, S.X. Bernhardt, et al. 2006. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. Bioconjug. Chem. 17:831-840.
76. Jelínkova, M., J. Strohalm, D. Plocova, et al. 1998. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J. Control. Release 52:253-270.
77. Jilani, I., E. Estey, Y. Huh, et al. 2002. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol. 118:560-566.
78. Johnson, D.A., and B.C. Laguzza. 1987. Antitumor xenograft activity with a conjugate of a vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Cancer Res. 47:3118-3122.
79. Jung, G., L. Grosse-Hovest, P.H. Krammer, et al. 2001. Target cell-restricted triggering of the CD95 (APO-1 /Fas) death receptor with bispecific antibody fragments. Cancer Res. 61:1846-1848.
80. Junutula, J.R., S. Bhakta, H. Raab, et al. 2008. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332:41-52.
81. Kallioniemi, O.P., U. Wagner, J. Kononen, et al. 2001. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum. Mol. Genet. 10:657-662.
82. Kawamoto, T., J. Shoda, N. Miyahara, et al. 2004. Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin. Exp. Metastasis 21:353-362.
83. Kinlough, C.L., P.A. Poland, J.B. Bruns, et al. 2004. MUC1 membrane trafficking is modulated by multiple interactions. J. Biol. Chem. 279:53071-53077.
84. Kirchhausen, T. 1999. Adaptors for clathrin-mediated traffic. Annu. Rev. Cell Dev. Biol. 15:705-732.
85. Kirkham, M., and R.G. Parton. 2005. Clathrin-independent endocytosis: New insights into caveolae and non-caveolar lipid raft carriers. Biochim. Biophys. Acta 1746:349-363.
86. Kluger, M.S., S.L. Shiao, A.L. Bothwell, et al. 2002. Cutting Edge. Internalization of transduced E-selectin by cultured human endothelial cells: Comparison of dermal microvascular and umbilical vein cells and identification of a phosphoserine-type di-leucine motif. J. Immunol. 168:2091-2095.
87. Kneile, J.R., G. Tan, S. Suster, et al. 2006. Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undiffer-entiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma. Histopathology 48:855-861.
88. Knoll, K., W. Wrasidlo, J.E. Scherberich, et al. 2000. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin theta11. Cancer Res. 60:6089-6094.
89. Kononen, J., L. Bubendorf, A. Kallioniemi, et al. 1998. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med. 4:844-847.
90. Kovtun, Y.V., C.A. Audette, Y. Ye, et al. 2006. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66:3214-3221.
91. Kreitman, R.J., and I. Pastan. 2006. Immunotoxins in the treatment of hematologic malignancies. Curr. Drug Targets 7:1301-1311.
92. Kupchan, S. 1972. Maytansine. J. Am. Chem. Soc. 94:1354-1356.
93. Ladino, C.A., R.V. Chari, L.A. Bourret, et al. 1997. Folate-maytansinoids: Target-selective drugs of low molecular weight. Int. J. Cancer 73:859-864.
94. Laguzza, B.C., C.L. Nichols, S.L. Briggs, et al. 1989. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. J. Med. Chem. 32:548-555.
95. Lajoie, P., and I.R. Nabi. 2007. Regulation of raft-dependent endocytosis. J. Cell. Mol. Med. 11:644-653.
96. Lamaze, C., A. Dujeancourt, T. Baba, et al. 2001. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol. Cell 7:661-671.
97. Larson, R.A., M. Boogaerts, E. Estey, et al. 2002. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16:1627-1636.
98. Larson, R.A., E.L. Sievers, E.A. Stadtmauer, et al. 2005. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452.
99. Laude, A.J., and I.A. Prior. 2004. Plasma membrane microdomains: Organization, function and trafficking. Mol. Membr. Biol. 21:193-205.
100. Law, C.L., C.G. Cerveny, K.A. Gordon, et al. 2004. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin. Cancer Res. 10:7842-7851.
101. Law, C.L., K.A. Gordon, B.E. Toki, et al. 2006. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res. 66:2328-2337.
102. Lee, M. 1987a. Calicheamicins. I. J. Am. Chem. Soc. 109:3464-3466.
103. Lee, M. 1987b. Calicheamicins. II. J. Am. Chem. Soc. 109:3466-3468.
104. Legrand, O., M.B. Vidriales, X. Thomas, et al. 2007. An open label, dose escalation study of AVE9633 administered as a single agent by intravenous (IV) infusion weekly for 2 weeks in 4-week cycle to patients with relapsed or refractory CD33-positive acute myeloid leukemia (AML). Abstract No. 1850. Blood 110(11).
105. Leuschner, C., and W. Hansel. 2005. Targeting breast and prostate cancers through their hormone receptors. Biol. Reprod. 73:860-865.
106. Linenberger, M.L., T. Hong, D. Flowers, et al. 2001. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98:988-994.
107. Liu, C., B.M. Tadayoni, L.A. Bourret, et al. 1996. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. U.S.A. 93:8618-8623.
108. Lode, H.N., R.A. Reisfeld, R. Handgretinger, et al. 1998. Targeted therapy with a novel enediyene antibiotic cali-cheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 58:2925-2928.
109. Lu, Y., E. Sega, C.P. Leamon, et al. 2004. Folate receptor-targeted immunotherapy of cancer: Mechanism and therapeutic potential. Adv. Drug Deliv. Rev. 56:1161-1176.
110. Luesch, H., R.E. Moore, V.J. Paul, et al. 2001. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 64:907-910.
111. Lum, L.G., P.A. Davol, and R.J. Lee. 2006. The new face of bispecific antibodies: Targeting cancer and much more. Exp. Hematol. 34:1-6.
112. Lyu, M.A., L.H. Cheung, W.N. Hittelman, et al. 2007. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol. Cancer Ther. 6:460-470.
113. Ma, D., C.E. Hopf, A.D. Malewicz, et al. 2006. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12:2591-2596.
114. Mahmood, I., and M.D. Green. 2005. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin. Pharmacokinet. 44:331-347.
115. Manabe, Y., T. Tsubota, Y. Haruta, et al. 1984. Production of a monoclonal antibody-methotrexate conjugate utilizing dextran T-40 and its biologic activity. J. Lab. Clin. Med. 104:445-454.
116. Mao, W., E. Luis, S. Ross, et al. 2004. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 64:781-788.
117. Marmor, M.D., and Y. Yarden. 2004. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23:2057-2070.
118. McDonagh, C.F., E. Turcott, L. Westendorf, et al. 2006. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Design Select. 19:299-307.
119. McEarchern, J.A., E. Oflazoglu, L. Francisco, et al. 2007. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109:1185-1192.
120. McGrath, M.S., M.G. Rosenblum, M.R. Philips, et al. 2003. Immunotoxin resistance in multidrug resistant cells. Cancer Res. 63:72-79.
121. Mellman, I., R. Fuchs, and A. Helenius. 1986. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 55:663-700.
122. Mohamed, M.M., and B.F. Sloane. 2006. Cysteine cathepsins: Multifunctional enzymes in cancer. Nature Rev. Cancer 6:764-775.
123. Mohamedali, K.A., D. Kedar, P. Sweeney, et al. 2005. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7:912-920.
124. Mosure, K.W., A.J. Henderson, L.J. Klunk, et al. 1997. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother. Pharmacol. 40:251-258.
125. Mousavi, S.A., M. Sporstol, C. Fladeby, et al. 2007. Receptor-mediated endocytosis of immune complexes in rat liver sinusoidal endothelial cells is mediated by FcgammaRIIb2. Hepatology 46:871-884.
126. Muro, H., H. Shirasawa, I. Kosugi, et al. 1993. Defect of Fc receptors and phenotypical changes in sinusoidal endothelial cells in human liver cirrhosis. Am. J. Pathol. 143:105-120.
127. Nagy, A., and A.V. Schally. 2005. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A "smarter" chemotherapy. Curr. Pharm. Design 11:1167-1180.
128. Natsume, A., M. Wakitani, N. Yamane-Ohnuki, et al. 2006. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J. Biochem. 140:359-368.
129. Ng, R., and M.D. Green. 2007. Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin. Drug Saf. 6:315-321.
130. Nimmerjahn, F., and J.V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19:239-245.
131. Odorizzi, C.G., I.S. Trowbridge, L. Xue, et al. 1994. Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment. J. Cell Biol. 126:317-330.
132. Palermo, C., and J.A. Joyce. 2008. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 29:22-28.
133. Pastan, I., R. Hassan, D.J. FitzGerald, et al. 2007. Immunotoxin treatment of cancer. Annu. Rev. Med. 58:221-237.
134. Pelkmans, L., and A. Helenius. 2002. Endocytosis via caveolae. Traffic 3:311-320.
135. Petersen, B.H., S.V. DeHerdt, D.W. Schneck, et al. 1991. Thehuman immune response to KS1/4-desacetylvinblas-tine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 51:2286-2290.
136. Pettit, G. 1987. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J.Am. Chem. Soc. 109:6883-6885.
137. Pettit, G. 1989. The absolute configuration and synthesis of natural (-)-dolastatin 10. J. Am. Chem. Soc. 111:5463-5465.
138. Pettit, G.R.B., and J. Barkoczy, inventors; University of Arizona, assignee. 1997. Tumor inhibiting tetrapeptide bearing modified phenethyl amines. U.S. Patent 5635483.
139. Pillay, C.S., E. Elliott, and C. Dennison. 2002. Endolysosomal proteolysis and its regulation. Biochem. J. 363:417-429.
140. Pimm, M.V., M.A. Paul, Y. Ogumuyiwa, et al. 1988. Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts. Cancer Immunol. Immunother. 27:267-271.
141. Pollack, V.A., E. Alvarez, K.F. Tse, et al. 2007. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother. Pharmacol. 60:423-435.
142. Polson, A.G., S.F. Yu, K. Elkins, et al. 2007. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 110:616-623.
143. Qu, Z., D.M. Goldenberg, T.M. Cardillo, et al. 2008. Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 111:2211-2219.
144. Rajagopal, A., and S.M. Simon. 2003. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 14:3389-3399.
145. Rajasekaran, S.A., G. Anilkumar, E. Oshima, et al. 2003. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 14:4835-4845.
146. Rakha, E.A., R.W. Boyce, D. Abd El-Rehim, et al. 2005. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod. Pathol. 18:1295-1304.
147. Reddy, J.A., E. Westrick, H.K. Santhapuram, et al. 2007. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res. 67:6376-6382.
148. Rihova, B., A. Jegorov, J. Strohalm, et al. 1992. Antibody-targeted cyclosporin A. J. Control. Release 19:25-39.
149. Rodon, J., M. Garrison, L.A. Hammond, et al. 2008. Cantuzumab mertansine in a three-times a week schedule: A phase I and pharmacokinetic study. Cancer Chemother. Pharmacol. 62:911-919.
150. Ross, H.J., L.L. Hart, P.M. Swanson, et al. 2006. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 54:69-77.
151. Ross, S., S.D. Spencer, I. Holcomb, et al. 2002. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62:2546-2553.
152. Rubinfeld, B., A. Upadhyay, S.L. Clark, et al. 2006. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nature Biotechnol. 24:205-209.
153. Ryan, M.C., M. Hering, D. Peckham, et al. 2007. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol. CancerTher. 6:3009-3018.
154. Saito, G., J.A. Swanson, and K.D. Lee. 2003. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55:199-215.
155. Saleh, M.N., S. Sugarman, J. Murray, et al. 2000. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18:2282-2292.
156. Sanderson, R.J., M.A. Hering, S.F. James, et al. 2005. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res. 11:843-852.
157. Sanz, L., B. Blanco, and L. Alvarez-Vallina. 2004. Antibodies and gene therapy: Teaching old "magic bullets" new tricks. Trends Immunol. 25:85-91.
158. Sauter, A., C. Kloft, S. Gronau, et al. 2007. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertan-sine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 30:927-935.
159. Sauter, G., R. Simon, and K. Hillan. 2003. Tissue microarrays in drug discovery. Nature Rev. Drug Discov. 2:962-972.
160. Schreiber, G.J., K.E. Hellstrom, and I. Hellstrom. 1992. An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res. 52:3262-3266.
161. Setiadi, H., and R.P. McEver. 2008. Clustering endothelial E-selectin in clathrin-coated pits and lipid rafts enhances leukocyte adhesion under flow. Blood 111:1989-1998.
162. Shen, W.C., and H.J. Ryser. 1984. Selective killing of Fc-receptor-bearing tumor cells through endocytosis of a drug-carrying immune complex. Proc. Natl. Acad. Sci. U.S.A. 81:1445-1447.
163. Shields, R.L., A.K. Namenuk, K. Hong, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:6591-6604.
164. Shimamura, T., S.R. Husain, and R.K. Puri. 2006. The IL-4 and IL-13 pseudomonas exotoxins: New hope for brain tumor therapy. Neurosurg. Focus 20:E11.
165. Sievers, E.L., F.R. Appelbaum, R.T. Spielberger, et al. 1999. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93:3678-3684.
166. Sievers, E.L., R.A. Larson, E.A. Stadtmauer, et al. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:3244-3254.
167. Sigal, L.H. 2007. Basic science for the clinician 46: Fcgamma receptors. J. Clin. Rheumatol. 13:355-358.
168. Simons, K., and E. Ikonen. 1997. Functional rafts in cell membranes. Nature 387:569-572.
169. Simons, K., and D. Toomre. 2000. Lipid rafts and signal transduction. Nature Rev. Mol. Cell. Biol. 1:31-39.
170. Skerra, A. 2000. Engineered protein scaffolds for molecular recognition. J. Mol. Recognit. 13:167-187.
171. Skerra, A. 2007. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18:295-304.
172. Slepnev, V.I., and P. De Camilli. 2000. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nature Rev. Neurosci. 1:161-172.
173. Smith-Jones, P.M. 2004. Radioimmunotherapy of prostate cancer. Quart. J. Nuclear Med. Mol. Imaging 48:297-304.
174. Smith, L.M., A. Nesterova, S.C. Alley, et al. 2006. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther. 5:1474-1482.
175. Spearman, M.E., R.M. Goodwin, L.D. Apelgren, et al. 1987. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J. Pharmacol. Exp. Ther. 241:695-703.
176. Spearman, M.E., R.M. Goodwin, and D. Kau. 1987. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. Drug Metab. Dispos. 15:640-647.
177. St'astny, M., K. Ulbrich, J. Strohalm, et al. 1997. Abnormal differentiation of thymocytes induced by free cyclos-porine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used. Transplantation 63:1818-1827.
178. Stasi, R., M.L. Evangelista, F. Buccisano, et al. 2008. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat. Rev. 34:49-60.
179. Stish, B.J., H. Chen, Y. Shu, et al. 2007. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin. CancerRes. 13:6486-6493.
180. Sun, M.M., K.S. Beam, C.G. Cerveny, et al. 2005. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 16:1282-1290.
181. Sutherland, M.S., R.J. Sanderson, K.A. Gordon, et al. 2006. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281:10540-10547.
182. Suzuki, H., J. Shoda, T. Kawamoto, et al. 2004. Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma. Clin. Exp. Metastasis 21:321-329.
183. Sznol, M., D. Sanders, H. Kluger, et al. 2007. A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma. 19th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics: Abstract # B47.
184. Tammi, R., K. Rilla, J.P. Pienimaki, et al. 2001. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J. Biol. Chem. 276:35111-35122.
185. Tarrago-Trani, M.T., and B. Storrie. 2007. Alternate routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum. Adv. Drug Deliv. Rev. 59:782-797.
186. Tassone, P., V.S. Goldmacher, P. Neri, et al. 2004a. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688-3696.
187. Tassone, P., A. Gozzini, V. Goldmacher, et al. 2004b. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. CancerRes. 64:4629-4636.
188. Tateno, H., H. Li, M.J. Schur, et al. 2007. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 27:5699-5710.
189. Taylor, V.C., C.D. Buckley, M. Douglas, et al. 1999. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 274:1150511512.
190. Tedder, T.F., M. Inaoki, and S. Sato. 1997. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6:107-118.
191. Temming, K., D.L. Meyer, R. Zabinski, et al. 2006. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug. Chem. 17:1385-1394.
192. Temming, K., D.L. Meyer, R. Zabinski, et al. 2007. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative. Mol. Pharm. 4:686-694.
193. Thurber, G.M., M.M. Schmidt, and K.D. Wittrup. 2008. Factors determining antibody distribution in tumors. Trends Pharmacol. Sci. 29:57-61.
194. Tijink, B.M., J. Buter, R. de Bree, et al. 2006. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. CancerRes. 12:6064-6072.
195. Tolcher, A.W., L. Ochoa, L.A. Hammond, et al. 2003. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21:211-222.
196. Tolcher, A.W., S. Sugarman, K.A. Gelmon, et al. 1999. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 17:478-484.
197. Trail, P.A., D. Willner, S.J. Lasch, et al. 1993. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215.
198. Trikha, M., Z. Zhou, J.A. Nemeth, et al. 2004. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer 110:326-335.
199. Tse, K.F., M. Jeffers, V.A. Pollack, et al. 2006. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 12:1373-1382.
200. Turturro, F. 2007. Denileukin diftitox: A biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev. Anticancer Ther. 7:11-17.
201. Uadia, P., A.H. Blair, and T. Ghose. 1984. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglo-bulin conjugate in EL4 lymphoma-bearing mice. Cancer Res. 44:4263-4266.
202. Uadia, P., A.H. Blair, T. Ghose, et al. 1985. Uptake of methotrexate linked to polyclonal and monoclonal antime-lanoma antibodies by a human melanoma cell line. J. Natl. Cancer Inst. 74:29-35.
203. Ulvestad, E., K. Williams, C. Vedeler, et al. 1994. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J. Neurol. Sci. 121:125-131.
204. Vallabhajosula, S., P.M. Smith-Jones, V. Navarro, et al. 2004. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice. Prostate 58:145-155.
205. van Der Velden, V.H., J.G. te Marvelde, P.G. Hoogeveen, et al. 2001. Targeting of the CD33-calicheamicin immu-noconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97:3197-3204.
206. van Roon, J.A., J.W. Bijlsma, J.G. van de Winkel, et al. 2005. Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate. Ann. Rheum. Dis. 64:865-870.
207. Varki, A., and T. Angata. 2006. Siglecs: The major subfamily of I-type lectins. Glycobiology 16:1R-27R.
208. Vedeler, C.A., R. Matre, E.K. Kristoffersen, et al. 1991. IgG Fc receptor heterogeneity in human peripheral nerves. ActaNeurol. Scand. 84:177-180.
209. Walter, R.B., P. Hausermann, B.W. Raden, et al. 2008a. Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. Traffic 9:267-279.
210. Walter, R.B., B.W. Raden, D.M. Kamikura, et al. 2005. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105:1295-1302.
211. Walter, R.B., B.W. Raden, R. Zeng, et al. 2008b. ITIM-dependent endocytosis of CD33-related Siglecs: Role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. J. Leukoc. Biol. 83:200-211.
212. Wang, L., G. Amphlett, W.A. Blattler, et al. 2005. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14:2436-2446.
213. Winchester, B. 2005. Lysosomal metabolism of glycoproteins. Glycobiology 15:1R-15R.
214. Wischhusen, J., G. Jung, I. Radovanovic, et al. 2002. Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 62:2592-2599.
215. Wischhusen, J., D. Schneider, M. Mittelbronn, et al. 2005. Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system. J. Neuroimmunol. 162:28-42.
216. Wolf, E., R. Hofmeister, P. Kufer, et al. 2005. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today 10:1237-1244.
217. Wu, A.M., and P.D. Senter. 2005. Arming antibodies: Prospects and challenges for immunoconjugates. Nature Biotechnol. 23:1137-1146.
218. Wu, C., H. Ying, C. Grinnell, et al. 2007. Simultaneous targeting of multiple disease mediators by a dual-variabledomain immunoglobulin. Nature Biotechnol. 25:1290-1297.
219. Xie, H., C. Audette, M. Hoffee, et al. 2004. Pharmacokinetics and biodistribution of the antitumor immunoconju-gate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J. Pharmacol. Exp. Ther. 308:1073-1082.
220. Yang, K., A. Basu, M. Wang, et al. 2003. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16:761-770.
221. Younes, A., A. Forero-Torres, N. Bartlett, et al. 2007. A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: Preliminary results of a phase I tolerability study. Haematologica 92(s5):63.
222. Zein, N., A.M. Sinha, W.J. McGahren, et al. 1988. Calicheamicin gamma 11: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198-1201.